Bicycle Therapeutics Plc ADR

BCYCNASDAQ · USD
3.20USD0.00 (+0.63%)
652

Bicycle Therapeutics Plc ADR (BCYC) Implied Volatility Current

BCYC's 30 day implied volatility is 360.19%, with an IV Rank of 86.11%. This is a high IV Rank versus the past year, meaning Bicycle Therapeutics Plc ADR options are relatively expensive and currently favor sellers. BCYC's 30 day historical volatility sits at 50.98%, which means implied volatility is running 309.21 points above historical volatility, as of Nov 17, 2026.

Read more

Tracking BCYC implied volatility helps you spot when Bicycle Therapeutics Plc ADR options are historically cheap or expensive, and where the best trades are hiding. When BCYC IV rises, premiums increase and sellers get more attractive pricing, and when it drops, buyers find cheaper contracts. Use our scanner to monitor BCYC implied volatility current levels in real time and filter for high probability trades.

Implied volatility is derived from option prices and represents the annualized expected move of a stock. Tracking BCYC IV rank helps you see whether BCYC's implied volatility is historically high or low, since IV rank compares today's reading against the past year's range. A high rank signals relatively expensive premiums and tends to favor sellers, a low rank signals relatively cheap premiums and tends to favor buyers.

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase.

Implied Volatility

IV Rank
86.11%IV Rank
High

IV is highly elevated. Premiums are expensive, strongly favoring sellers.

Implied Volatility (30d)360.19%

IV Rank86.11%

Historical Volatility (30d)50.98%

IV Minus HV+309.21%

As of Nov 17, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →